Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Wallace Daniel J.; Furie Richard A.; Tanaka Yoshiya; Kalunian Kenneth C.; Mosca Marta; Petri Michelle A.; Doerner Thomas; Cardiel Mario H.; Bruce Ian N.; Gomez Elisa; Carmack Tara; DeLozier Amy M.; Janes Jonathan M.; Linnik Matthew D.; de Bono Stephanie; Silk Maria E.; Hoffman Robert W.

首页> 外文期刊>The Lancet >Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

【24h】

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

机译：Systemic Lupus红斑狼疮的Baricitinib：双盲，随机，安慰剂控制，第2期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus.

机译：背景技术狼疮红斑狼疮具有大量未满足的医疗需求。 Baricitinib是一种口服选择性Janus激酶（Jak）1和Jak2抑制剂，我们假设可以对系统性红斑狼疮患者具有治疗益处。

著录项

来源
《The Lancet》 |2018年第10143期|共10页
作者
Wallace Daniel J.; Furie Richard A.; Tanaka Yoshiya; Kalunian Kenneth C.; Mosca Marta; Petri Michelle A.; Doerner Thomas; Cardiel Mario H.; Bruce Ian N.; Gomez Elisa; Carmack Tara; DeLozier Amy M.; Janes Jonathan M.; Linnik Matthew D.; de Bono Stephanie; Silk Maria E.; Hoffman Robert W.;
展开▼
作者单位

Univ Calif Los Angeles Cedars Sinai Med Ctr Div Rheumatol Los Angeles CA 90048 USA;

Hofstra Div Rheumatol Zucker Sch Med New York NY USA;

Univ Occupat &

Environm Hlth Sch Med Dept Internal Med 1 Kitakyushu Fukuoka Japan;

Univ Calif San Diego Sch Med Div Rheumatol La Jolla CA 92093 USA;

Univ Pisa Div Rheumatol Pisa Italy;

Johns Hopkins Univ Sch Med Div Rheumatol Baltimore MD USA;

Charite Univ Med Berlin Div Rheumatol Berlin Germany;

Ctr Invest Clin Morelia SC Morelia Michoacan Mexico;

Univ Manchester Fac Biol Med &

Hlth Arthrit Res UK Ctr Epidemiol Manchester Lancs England;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Lilly Biotechnol Ctr San Diego CA USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018) [J] . Wallace D. J., Furie R. A., Tanaka Y. The Lancet . 2018,第10146期

机译：Systemic Lupus红斑狼疮：双盲，随机，安慰剂控制，第2阶段试验（第392 Vol 392，PG 222,2018）
2. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial [J] . Merrill Joan T., Shanahan William R., Scheinberg Morton, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第6期

机译：第III期试验结果与Blisibimod，B细胞活化因子的选择性抑制剂，在具有全身性狼疮的受试者中（SLE）：来自随机，双盲，安慰剂对照试验的结果
3. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled phase IIb clinical trial [J] . ZimmerR., ScherbarthH.R., RilloO.L., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2013,第11期

机译：系统性红斑狼疮患者的Lupuzor / P140肽：一项随机，双盲，安慰剂对照的IIb期临床试验
4. Serum Levels of Leptin in Patients with Systemic Lupus Erythematosus: Correlated with Lupus Activity [C] . XU Ting, JIN Ou-yang, ZHAO Sheng-nan, International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) . 2007

机译：系统性红斑狼疮患者血清瘦素水平：与狼疮活动相关
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre double-blind randomised placebo-controlled 52-week phase II clinical trial [O] . Alexis Jones, Patrick Muller, Caroline J Dore, 2019

机译：系统性红斑狼疮（BEAT狼疮）患者进行B细胞耗竭治疗后的Belimumab方案：一项前瞻性多中心双盲随机安慰剂对照52周的II期临床试验
7. POS0686 BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL [O] . T. Dörner, R. Van Vollenhoven, A. Doria, 2021

机译：POS0686 Baricitinib在具有Systemic Lupus红斑狼疮的成人中降低了抗DSDNA和IgG抗体，从相2双盲，随机，安慰剂对照试验

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅